Caribou Biosciences, Inc. (CRBU)

Sentiment-Signal

22,0

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Unternehmen & Branche

Name	Caribou Biosciences, Inc.
Ticker	CRBU
CIK	0001619856
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	182,2 Mio. USD
Beta	2,46
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	11,159,000	-148,125,000	-1.59	175,367,000	122,175,000
2025-09-30	10-Q	2,198,000	-27,548,000	-0.30	194,984,000	141,845,000
2025-06-30	10-Q	2,667,000	-54,098,000	-0.58	220,903,000	166,132,000
2025-03-31	10-Q	2,353,000	-39,991,000	-0.43	273,656,000	217,222,000
2024-12-31	10-K	9,994,000	-149,105,000	-1.65	313,313,000	252,951,000
2024-09-30	10-Q	2,024,000	-34,684,000	-0.38	344,334,000	281,203,000
2024-06-30	10-Q	3,464,000	-37,697,000	-0.42	372,938,000	310,464,000
2024-03-31	10-Q	2,429,000	-41,234,000	-0.46	406,825,000	343,289,000
2023-12-31	10-K	34,477,000	-102,070,000	-1.38	432,209,000	368,401,000
2023-09-30	10-Q	23,662,000	-10,002,000	-0.12	457,521,000	398,268,000
2023-06-30	10-Q	3,755,000	-29,519,000	-0.48	349,647,000	269,458,000
2023-03-31	10-Q	3,502,000	-28,044,000	-0.46	347,462,000	278,272,000
2022-12-31	10-K	13,851,000	-99,421,000	-1.64	373,765,000	300,871,000
2022-09-30	10-Q	3,303,000	-26,647,000	-0.44	398,823,000	324,114,000
2022-06-30	10-Q	4,192,000	-26,697,000	-0.44	421,367,000	347,889,000
2022-03-31	10-Q	2,664,000	-19,088,000	-0.32	445,997,000	371,797,000
2021-12-31	10-K	2,559,000	-18,479,000	-2.11	442,356,000	387,825,000
2021-09-30	10-K	3,977,000	-20,974,000
2021-09-30	10-Q	3,977,000	-20,974,000	-0.46	461,960,000	404,401,000
2021-06-30	10-K	1,476,000	-14,311,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-02-25	Kelly Timothy P	Officer, Chief Technology Officer	Open Market Sale	-6,228	1.93	-12,020.04	-126,6%
2026-02-24	Kelly Timothy P	Officer, Chief Technology Officer	Open Market Sale	-3,147	1.96	-6,168.12	-65,0%
2026-02-24	MCCLUNG BARBARA G	Officer, Chief Legal Officer	Open Market Sale	-6,938	1.96	-13,598.48	-143,2%
2026-02-24	Khan Ruhi Ahmad	Officer, Chief Business Officer	Open Market Sale	-6,938	1.96	-13,598.48	-143,2%
2026-02-24	Albertson Tina M.	Officer, Chief Medical Officer	Open Market Sale	-1,066	1.96	-2,089.36	-22,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.